Post by Boehringer Ingelheim

#NEWS: We are advancing our pipeline in obesity and metabolic health with initiation of a Phase II trial for our investigational triple receptor agonist. This trial marks another step towards addressing #obesity by targeting complementary pathways that drive body weight, metabolism, and eating behavior.   Read more 👉 https://lnkd.in/ddHiM86r   #LifeForward